Ginkgo Bioworks (NYSE: DNA) reported Q2 EPS of ($0.41), $0.36 worse than the analyst estimate of ($0.05). Revenue for the quarter came in at $145 million versus the consensus estimate of $78.83 million.

GUIDANCE:

Ginkgo Bioworks sees FY2022 revenue of $425-440 million, versus the consensus of $393 million.

For earnings history and earnings-related data on Ginkgo Bioworks (DNA) click here.